VRPX (Virpax Pharmaceuticals) Common Stock: $0.00 Mil (As of Dec. 2024)


What is Virpax Pharmaceuticals Common Stock?

Virpax Pharmaceuticals VRPX Common Stock is $0.00 Mil as of Dec. 2024.

Virpax Pharmaceuticals Common Stock Historical Data

* Premium members only.

The historical data trend for Virpax Pharmaceuticals's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Virpax Pharmaceuticals Common Stock Chart

Virpax Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Common Stock
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Virpax Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Virpax Pharmaceuticals Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $0.00 Mil mean?
Virpax Pharmaceuticals (VRPX) has a Common Stock of $0.00 Mil as of Dec. 2024. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Virpax Pharmaceuticals and its competitors.
Is Virpax Pharmaceuticals' Common Stock too high?
Virpax Pharmaceuticals' current Common Stock is $0.00 Mil.
How does Virpax Pharmaceuticals' Common Stock compare to SYGGF and SCPX?
Virpax Pharmaceuticals' Common Stock of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Virpax Pharmaceuticals and its competitors. Virpax Pharmaceuticals's current Common Stock is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virpax Pharmaceuticals stock overvalued right now?
Virpax Pharmaceuticals (VRPX) has a current Common Stock of $0.00 Mil. The current Common Stock is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Virpax Pharmaceuticals (VRPX), the current Common Stock is $0.00 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Virpax Pharmaceuticals Business Description

Address 1055 Westlakes Drive, Suite 300, Berwyn, PA, USA, 19312
Virpax Pharmaceuticals Inc is a preclinical stage biopharmaceutical company. The company is focused on developing pharmaceutical product candidates for pain management. Its product portfolio includes Topical metered-dose spray; Liposomal in Hydrogel encapsulation; and Enkephalin Intranasal spray.